Name (Synonyms) | Correlation | |
---|---|---|
drug1366 | oxygen treatment Wiki | 1.00 |
drug850 | Placebo Wiki | 0.09 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This study will enroll 40 symptomatic outpatients tested positive for Coronavirus 2019 (COVID-19). Patients to be randomized 1:1 to Telmisartan (40 mg) vs placebo to be administered orally once daily x 21 days. Daily, the study patients will be asked to keep a record of the severity of their fever, dyspnea and fatigue and take their blood pressure (BP) and temperature. Study visits to occur on day 1 (entry), day 4, day 10 and day 21. Oro-pharyngeal swabs, and approximately 25 cc of blood will be collected at each study visit for safety labs and for the evaluation of the renin-angiotensin system (RAS) system and for various blood biomarkers of inflammation, coagulation and fibrosis.
Description: Based on a modified World Health Organization (WHO) COVID-19 7-point ordinal scale
Measure: Maximum clinical severity of disease Time: Over the 21 day period of studyDescription: Number of adverse events grade 2 and above utilizing the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0, November 2014
Measure: Incidence of treatment emergent adverse events Time: Through study completion at day 21 of studyDescription: Angiotensin I (AngI), AngII, Ang1-9 and Ang1-7
Measure: Renin angiotensin system peptides Time: At each study time point (day 4, day 10, day 21)Description: plasma biomarkers of organ function/coagulation, inflammation, leukocyte chemotaxis, tissue remodeling/fibrosis and immune exhaustion by Luminex multiplexing assays such as TNF-alpha, IL-6, CK-MB, Troponin I, Fractalkine, MCP-1, PD-1, TIMP-1
Measure: Plasma biomarkers Time: At each study time point (day 4, day 10, day 21)